Live feed07:30:00·25dPRReleasevia QuantisnowNervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic TetraplegiaByQuantisnow·Wall Street's wire, on your screen.NGEN· NervGen Pharma Corp.
